HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

被引：0
|
作者：
Catalina Falo
Abelardo Moreno
Mar Varela
Belen Lloveras
Agnès Figueras
Agustín Escobedo
机构：
[1] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[2] Hospital Universitari de Bellvitge,Department of Medical Oncology, Breast Cancer Unit, Institut Català d’Oncologia
[3] Hospital Duran i Reynals,Department of Pathology, Breast Cancer Unit
[4] Hospital Universitari de Bellvitge,Tumour Bank, Institut Català d’Oncologia
[5] Hospital Duran i Reynals,Department of Pathology, Institut Català d’Oncologia
[6] Hospital Duran i Reynals,Translational Research Laboratory, Institut Català d’Oncologia
[7] Hospital Duran i Reynals,Breast Cancer Unit, Institut Català d’Oncologia
[8] Hospital Duran i Reynals,Unitat Funcional de Mama
[9] Institut Català d’Oncologia,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2007年 / 133卷
关键词：
Breast carcinoma; Her-2/; Primary chemotherapy; Response; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：423 / 429
页数：6
相关论文
共 50 条
  • [31] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
  • [32] Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Mazouni, Chafika
    Hall, Angeline
    Broglio, Kristine
    Fritsche, Herbert
    Andre, Fabrice
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    Buzdar, Aman U.
    Pusztai, Lajos
    Cristofanilli, Massimo
    CANCER, 2007, 109 (03) : 496 - 501
  • [33] NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST CANCER: DATA FROM THE ASTER STUDY (AT FOR 3 CYCLES FOLLOWED BY CMF FOR 3 CYCLES)
    Puma, E.
    Mariani, P.
    Damian, S.
    Dazzani, M. C.
    De Benedictis, E.
    Parati, M.
    Sica, L.
    Tessari, A.
    De Braud, F. G. M.
    Moliterni, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 102
  • [34] Association between HER-2/neu status and clinicopathological characteristics of breast cancer
    Hazim, Ammar Imad
    Kaur, Gurjeet
    HEALTHMED, 2011, 5 (02): : 281 - 287
  • [35] The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer
    Hyun, C. L.
    Lee, H. E.
    Kim, K. S.
    Kim, S-W
    Kim, J. H.
    Choe, G.
    Park, S. Y.
    JOURNAL OF CLINICAL PATHOLOGY, 2008, 61 (03) : 317 - 321
  • [36] Express Analysis of HER-2/NEU Status in Breast Cancer Biopsy Specimens
    I. N. Nechaev
    E. N. Knyazev
    N. A. Krainova
    M. Yu. Shkurnikov
    Bulletin of Experimental Biology and Medicine, 2013, 155 : 522 - 526
  • [37] Express Analysis of HER-2/NEU Status in Breast Cancer Biopsy Specimens
    Nechaev, I. N.
    Knyazev, E. N.
    Krainova, N. A.
    Shkurnikov, M. Yu.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2013, 155 (04) : 522 - 526
  • [38] HER-2/neu status in breast cancer metastases to the central nervous system
    Lear-Kaul, KC
    Yoon, HR
    Kleinschmidt-DeMasters, BK
    McGavran, L
    Singh, M
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2003, 127 (11) : 1451 - 1457
  • [39] Risk of breast cancer according to the status of HER-2/neu oncogene amplification
    Huang, WY
    Newman, B
    Millikan, RC
    Conway, K
    Hulka, BS
    Schell, MJ
    Liu, ET
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2000, 9 (01) : 65 - 71
  • [40] Upregulation of HER-2/neu by Ovarian Ablation: Results of a Randomized Trial Comparing Leuprorelin to CMF as Adjuvant Therapy in Node-positive Breast Cancer Patients
    D. Lüftner
    A. Jung
    P. Schmid
    R. Geppert
    E. Kienle
    K.D. Wernecke
    K. Possinger
    Breast Cancer Research and Treatment, 2003, 80 : 245 - 255
12345